Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
PTC Therapeutics (PTCT)
:PTCT
Holding PTCT?
Track your performance easily
Earnings Data
Report Date
Feb 25, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.65Last Year’s EPS
-2.06Same Quarter Last Year
Moderate Buy
Based on 13 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 05, 2018
|% Change Since: 2.05%
|Next Earnings Date:Aug 07, 2018
Earnings Call Sentiment|Neutral
The earnings call highlighted strong financial performance, significant pipeline progress, and strategic NDA submissions and approvals. However, challenges remain in the European regulatory landscape and competitive pressures in the U.S. market.Company Guidance
In the third quarter of 2024, PTC Therapeutics achieved total revenue of $197 million, with $124 million derived from the DMD franchise, including $52 million from Emflaza. The company increased its 2024 total revenue guidance to $750 million to $800 million. PTC submitted two NDAs to the FDA for sepiapterin and Translarna, with the former having an action date on July 29, 2025. The company also plans to submit an NDA for vatiquinone in December, based on significant benefits observed in clinical trials. PTC's cash reserves exceed $1 billion, positioning it well for future developments. Additionally, the company's PTC518 program for Huntington's disease received fast track designation from the FDA, and the utreloxastat program for ALS is on schedule for top-line results.Strong Revenue Performance
Total revenue for the third quarter was $197 million, including $124 million from the DMD franchise and $52 million from Emflaza. The company's total cash position exceeded $1 billion.
NDA Submissions and Approvals
PTC submitted two NDAs to the FDA, for sepiapterin and Translarna, both of which have been accepted for filing. Sepiapterin's NDA includes significant efficacy evidence and is under review in multiple regions.
Significant Pipeline Progress
Fast track designation was received for PTC518 for Huntington's disease. The company is on schedule to submit an NDA for vatiquinone, based on significant long-term benefits observed in trials.
Global Expansion and New Market Entries
Translarna received first-time orders from two new countries in the Middle East and North Africa region. The sepiapterin global launch is planned for 2025 with submissions under review in multiple countries.
---
PTCT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PTCT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $42.96 | $44.28 | +3.07% |
| Aug 08, 2024 | $32.45 | $31.29 | -3.57% |
| Apr 25, 2024 | $25.49 | $28.57 | +12.08% |
| Feb 29, 2024 | $28.19 | $31.95 | +13.34% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does PTC Therapeutics (PTCT) report earnings?
PTC Therapeutics (PTCT) is schdueled to report earning on Feb 25, 2025, TBA Not Confirmed.
What is PTC Therapeutics (PTCT) earnings time?
PTC Therapeutics (PTCT) earnings time is at Feb 25, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PTCT EPS forecast?
PTCT EPS forecast for the fiscal quarter 2024 (Q4) is -0.65.
---